SCHEMBL3252246

SCHEMBL3252246

O=C(CNS(=O)(=O)c1cccc(C(F)(F)F)c1)Nc1ccc(Cl)cc1Cc1ccccc1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
RECQL P46063 1/20 0.52
PPARG P37231 2/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 4/20 0.45
PLCG1 P19174 1/20 0.45
TP53 P04637 1/20 0.44
SLC20A2 Q08357 1/20 0.42
SLC20A1 Q8WUM9 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
MEP1B Q16820 1/20 0.41
GAA P10253 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249160 0.87 ALDH1A1 (0.53) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL4866268 0.86 KAT6A (0.46) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL3247111 0.86 FLT1 (0.48) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL3253246 0.85 MEP1B (0.48) ALDH1A1MAPTMEP1BGAALMNA
SCHEMBL3255473 0.84 ALDH1A1 (0.47) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL3255565 0.83 MEP1B (0.55) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL4869124 0.83 GAA (0.44) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL4871474 0.83 FLT1 (0.52) ALDH1A1RECQLMEN1KMT2AMAPT
SCHEMBL4860809 0.82 L3MBTL1 (0.46) ALDH1A1MEN1KMT2AMAPTTP53
SCHEMBL3251190 0.82 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 ALDH1A1 2179/4885RECQL 2322/4885PPARG 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.